Loading…
Travere Therapeutics, Inc. is projected to rise to $88.55 by 2027, a +56% move from its current price of $56.59. TVTX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $55.46 | $56.63 | $57.82 | +0.06% |
| Jul 14 | $55.02 | $56.66 | $58.35 | +0.13% |
| Jul 15 | $54.69 | $56.70 | $58.78 | +0.19% |
| Jul 16 | $54.42 | $56.73 | $59.15 | +0.26% |
| Jul 17 | $54.19 | $56.77 | $59.47 | +0.32% |
| Jul 18 | $53.98 | $56.81 | $59.78 | +0.38% |
| Jul 19 | $53.80 | $56.84 | $60.06 | +0.45% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $53.80 | $56.84 | $60.06 | +0.45% |
| Week 2 | $52.82 | $57.10 | $61.72 | +0.90% |
| Week 3 | $52.14 | $57.35 | $63.09 | +1.35% |
| Week 4 | $51.60 | $57.61 | $64.31 | +1.80% |
| Week 5 | $51.17 | $57.87 | $65.45 | +2.26% |
| Week 6 | $50.79 | $58.13 | $66.52 | +2.71% |
| Week 7 | $50.47 | $58.39 | $67.54 | +3.17% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Travere Therapeutics, Inc. is a biopharmaceutical company focused on identifying, developing, and delivering therapies to people living with rare kidney and metabolic diseases in the United States. Its products include FILSPARI (sparsentan), a once-daily oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program.
Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.
Travere Therapeutics, Inc. (TVTX) is positioned as a specialty healthcare company focused on rare kidney and metabolic diseases. The stock’s current price is $55.95 with a market cap of $5.2B and a rank of 1330.
The latest price implies a near-term focus around the current level, while the long-run forecast points to a multi-year upside path. The year-by-year forecast shows a gradual ascent from the near term to substantial gains by the 2030s and beyond, with bullish sentiment prevailing in the later years.
A major floor 52.7% below — a decisive break under it would weaken the trend.
The nearest floor, 24.1% below — buyers have tended to step in here.
The nearest ceiling, 4.3% above — a clean break opens room to run.
A major ceiling 21.8% above — clearing it would confirm fresh momentum.
Key TVTX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TVTX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $57.75 | Sell | $57.51 | Sell |
| MA 10 | $57.60 | Sell | $57.16 | Sell |
| MA 20 | $56.06 | Buy | $55.36 | Buy |
| MA 50 | $49.14 | Buy | $49.77 | Buy |
| MA 100 | $40.32 | Buy | $43.79 | Buy |
| MA 200 | $36.01 | Buy | $37.13 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 60.68 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 17.73 | Neutral |
| Williams %R (14) | -62.24 | Info |
| MACD (12,26,9) | -0.38 | Sell |
| ROC (12) | 1.14 | Buy |
| Bollinger %B (20,2) | 0.55 | Neutral |
| Stochastic %K (14) | 37.76 | Neutral |
| TRIX (15) | 0.92 | Buy |
| Awesome (5,34) | 5.84 | Buy |
| Ultimate (7,14,28) | 52.61 | Neutral |
| Momentum (10) | -2.44 | Sell |
| Aroon Osc (25) | 60.00 | Buy |
| Hull MA (9) | 58.12 | Sell |
| ADX (14) | 35.94 | Buy |
| ATR (14) | 0.96 | Info |
The 30-day technical picture shows bullish sentiment. RSI(14) sits at 70, indicating upside momentum, with the near-term trend supported by a SMA50 of $44.82 and a SMA200 of $33.97. The stock faces resistance at $55.95 and has support at $42.26.
Over the last 30 days, the price has traded between $47.19 and $66.34, reflecting a rising expectation for further gains. Annualized volatility stands around 50%, signaling elevated price movement potential over the period.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $26.79 | $56.59 | $81.54 | 0% | Neutral | |
| $72.05 | $88.55 | $114.11 | +56% | Bullish | |
| $86.63 | $108.69 | $144.21 | +92% | Bullish | |
| $98.95 | $126.29 | $171.46 | +123% | Bullish | |
| $114.48 | $148.31 | $205.30 | +162% | Bullish | |
| $124.11 | $162.98 | $229.49 | +188% | Bullish | |
| $141.12 | $187.68 | $268.34 | +232% | Bullish | |
| $174.15 | $234.33 | $339.76 | +314% | Bullish | |
| $203.40 | $276.75 | $406.45 | +389% | Bullish | |
| $232.09 | $319.14 | $474.36 | +464% | Bullish | |
| $363.09 | $523.55 | $818.53 | +825% | Bullish | |
| $698.61 | $1,090.73 | $1,837.40 | +18.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $26.79 | $56.59 | $67.31 | +0.00% |
| August 2026 | $50.20 | $58.87 | $70.61 | +4.03% |
| September 2026 | $50.87 | $59.98 | $72.57 | +1.89% |
| October 2026 | $50.89 | $60.27 | $73.45 | +0.49% |
| November 2026 | $52.78 | $62.75 | $76.94 | +4.12% |
| December 2026 | $55.43 | $66.14 | $81.54 | +5.39% |
Click any year to see its month-by-month TVTX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, TVTX is projected to trade between $26.79 and $81.54, averaging $56.59 — a potential gain of 0% from today's $56.59. A consolidation phase looks the most probable path here.
Travere Therapeutics, Inc.'s 2027 outlook centres on $88.55, within a $72.05 to $114.11 range. That is up +56% on the projected 2026 average. That marks a +56% change versus current levels. Momentum favours further upside here.
By 2028, TVTX could reach as high as $144.21, with a base case around $108.69 and support toward $86.63 — roughly +92% from $56.59. Buyers look set to stay in control over this stretch.
Expect TVTX to range from $98.95 to $171.46 through 2029. The $126.29 average target implies a +123% move from current prices. That is up +16% on the projected 2028 average. Momentum favours further upside here.
The TVTX price prediction for 2030 points to an average of $148.31 (low $114.48, high $205.30) — a potential gain of +162% on today's $56.59. Buyers look set to stay in control over this stretch.
In 2031, TVTX is projected to trade between $124.11 and $229.49, averaging $162.98 — a potential gain of +188% from today's $56.59. That is up +10% on the projected 2030 average. Momentum favours further upside here.
Travere Therapeutics, Inc.'s 2032 outlook centres on $187.68, within a $141.12 to $268.34 range. That is up +15% on the projected 2031 average. That marks a +232% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, TVTX could reach as high as $339.76, with a base case around $234.33 and support toward $174.15 — roughly +314% from $56.59. Momentum favours further upside here.
Expect TVTX to range from $203.40 to $406.45 through 2034. The $276.75 average target implies a +389% move from current prices. That is up +18% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The TVTX price prediction for 2035 points to an average of $319.14 (low $232.09, high $474.36) — a potential gain of +464% on today's $56.59. Momentum favours further upside here.
In 2040, TVTX is projected to trade between $363.09 and $818.53, averaging $523.55 — a potential gain of +825% from today's $56.59. That is up +64% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Travere Therapeutics, Inc.'s 2050 outlook centres on $1,090.73, within a $698.61 to $1,837.40 range. That is up +108% on the projected 2040 average. That marks a +18.3x change versus current levels. Momentum favours further upside here.
Investing $1,000 in TVTX today (≈ 17.670967 TVTX) could be worth
$19,274.24
+$18,274.24 (+1827%) by 2050 · US Dollar
Based on the average projected TVTX price of $1,090.73 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TVTXwould be worth at today's price.
$1,000 invested in TVTX on Jul 10, 2025 (≈ 60.422964 TVTX) would be worth
$3,419.34
+$2,419.34 (+241.9%) today · 3.42× · US Dollar
Based on a TVTX entry price of $16.55 vs. today's $56.59.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $56.92 | $994.2 | -0.6% |
| 1 month ago | $46.74 | $1,210.74 | +21.1% |
| 3 months ago | $28.96 | $1,954.07 | +95.4% |
| 6 months ago | $34.1 | $1,659.53 | +66.0% |
| 1 year ago | $16.55 | $3,419.34 | +241.9% |
| All time (5.0y) ago | $14.29 | $3,960.11 | +296.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TVTX forecast.
Our base-case forecast reaches $110.00 around 2029.
Implied market cap at $110.00: $10.23B
The multi-year forecast points to a sustained upside for TVTX, with the 2026 average price at $55.95 (0% ROI) signaling a flat start before a stronger ascent in following years. By 2027 the average is $88.74 with a 58.6% ROI, and by 2028 the average rises to $111.75 (99.7% ROI). In 2029 the average is $126.02 (125.2% ROI), and by 2030 the average advances to $146.25 (161.4% ROI).
The trajectory remains bullish into later years, with 2040 averaging $520.59 (830.5% ROI) and 2050 averaging $1,040.53 (1,759.8% ROI). These are estimates, not guarantees, and depend on market conditions and company milestones.
Tap a question to reveal the answer.
According to the forecast, TVTX could average $146.25 in 2030, with a min of $109.32 and a max of $210.59, and an estimated ROI of 161.4%.
The forecast shows rising averages from 2027 onward (e.g., $88.74 in 2027 with a 58.6% ROI, $111.75 in 2028 with 99.7% ROI, and higher in subsequent years), indicating a bullish outlook over time. These are estimates, not guarantees, and should be weighed with risk considerations.
Yes. The 2030 max in the forecast is $210.59, which exceeds $200.
The current price is $55.95 and the market cap is $5.2B.
Bullish sentiment is indicated, with RSI(14) at 70. The SMA50 is $44.82 and the SMA200 is $33.97. The 30-day range is $47.19 to $66.34, with support at $42.26 and resistance at $55.95. Volatility is elevated at 50%.
Travere Therapeutics, Inc. Community Discussion
0Share your Travere Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.